Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
T

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can Achieve CR, MRD- Patients Have Better Survival, Many MRD Related Specifics Need to Be Defined

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Thomas Martin
November 18, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

27:54
Bristol Myers Squibb Hematology

Importance of Maintenance Therapy in MM Patients Post Auto-HSCT

Feat. B. Randolph

Featured Video

28:15
Bristol Myers Squibb Hematology

Considerations for Continuous Therapy in Multiple Myeloma

Feat. D. Landau

Related Content

AUTOPLAY
23:18
Oncology Data Advisor

Can Diet and Nutrition Impact Multiple Myeloma Outcomes?

Feat. U. Shah, R. Banerjee
10:50
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …

Feat. A. Jakubowiak
36:30
Bristol Myers Squibb Hematology

A Physician Perspective on Treating NSCT NDMM

Feat. F. Davies
33:28
Cleveland Clinic Taussig Cancer Institute

Management of Relapsed/Refractory Multiple Myeloma

Feat. F. Anwer
17:59
Parameswaran Hari

Delivering the Best Initial Treatment for Myeloma: Induction Therapy…

16:00
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate: How Much Is Too Much in NDMM - Triplet…

Feat. R. Baz
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Opti…

04:41
Joshua Richter

Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Tri…

15:12
Yale Cancer Center

ASH 2021: Cellular Therapies in Myeloma

Feat. N. Bar
27:54
Bristol Myers Squibb Hematology

Importance of Maintenance Therapy in MM Patients Post Auto-HSCT

Feat. B. Randolph
22:41
Ehsan Malek

Importance and Prospect of Maintenance Treatment in Post-SCT MM Pati…

10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Management of Multiple Myeloma: Smoldering Disease, Induction Therap…

Feat. K. Shain
26:02
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discuss…

Feat. J. Brayer
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Di…

Feat. K. Maples
13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Th…

Feat. A. Rosko
31:09
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Updates on BCMA CAR T-Cell for MM: Real World Experience and Future P…

Feat. M. Alsina
15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myel…